Description: Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer that have not been successfully treated with conventional therapeutics.
Home Page: www.oncolyticsbiotech.com
ONCY Technical Analysis
322 11th Avenue SW
Calgary,
AB
T2R 0C5
Canada
Phone:
403 670 7377
Officers
| Name | Title |
|---|---|
| Dr. Matthew C. Coffey M.B.A., Ph.D. | Pres, CEO & Director |
| Mr. Kirk J. Look C.A., CA | Chief Financial Officer |
| Mr. Andrew R. de Guttadauro | Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Ms. Allison Hagerman P.Eng., P.M.P. | VP of Product Devel. |
| Jon Patton | Director of Investor Relations & Communication |
| Dr. Grey Wilkinson Ph.D. | Scientist of Translational Medicine |
| Mr. John Mark Lievonen F.C.A., FCA | Consultant |
| Dr. Daniel Douglas Von Hoff F.A.C.P., FACP, M.D. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.1573 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 1999-11-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |